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Activating germlinemutations in STAT3were recently
identified as a cause of neonatal diabetes mellitus
associated with beta-cell autoimmunity. We have
investigated the effect of an activating mutation,
STAT3K392R, on pancreatic development using in-
duced pluripotent stem cells (iPSCs) derived from a
patient with neonatal diabetes and pancreatic hypo-
plasia. Early pancreatic endoderm differentiated
similarly from STAT3K392R and healthy-control cells,
but in later stages,NEUROG3expressionwasupregu-
lated prematurely in STAT3K392R cells together with
insulin (INS) and glucagon (GCG). RNA sequencing
(RNA-seq) showed robust NEUROG3 downstream
targets upregulation. STAT3 mutation correction
with CRISPR/Cas9 reversed completely the disease
phenotype. STAT3K392R-activating properties were
not explained fully by altered DNA-binding affinity or
increased phosphorylation. Instead, reporter assays
demonstrated NEUROG3 promoter activation by
STAT3 in pancreatic cells. Furthermore, proteomic
and immunocytochemical analyses revealed in-
creased nuclear translocation of STAT3K392R. Collec-
tively, our results demonstrate that the STAT3K392R
mutation causes premature endocrine differentiation
through direct induction of NEUROG3 expression.
INTRODUCTION
The pancreas is a multifunctional organ, consisting of two func-
tionally distinct compartments that originate from the posteriorC
This is an open access article under the CC BY-Nforegut endoderm. The acinar and ductal cells of the exocrine
compartment are derived from the tip and trunk regions of the
branched pancreatic epithelium, respectively (Jennings et al.,
2015; Pan and Wright, 2011; Puri et al., 2015). The endocrine
pancreas develops from trunk cells that upregulate Neurogenin3
(NEUROG3). These cells delaminate from the pancreatic epithe-
lium to form the islets of Langerhans. The islets contain fivemajor
endocrine cell types that regulate nutrient metabolism and
glucose homeostasis and secrete glucagon (a), insulin (b), so-
matostatin (d), ghrelin (ε), or pancreatic polypeptide (g). Elucida-
tion of the molecular mechanisms controlling the development
and function of these cells is essential to an improved under-
standing of the underlying causes of diabetes, a major global
health problem (WHO, 2016).
Signal transducer and activator of transcription 3 (STAT3) is a
critical component of cytokine signaling that regulates a diversity
of cellular processes. The role of STAT3 has been best estab-
lished in the immune system (O’Shea and Plenge, 2012), where
it mediates the transcriptional responses to several cytokines
(e.g., interleukin-6 [IL-6], IL-10, and leukemia inhibitory factor
[LIF]) acting via receptors coupled to members of the Janus ki-
nase (JAK) family, which in turn phosphorylate STAT proteins.
The STAT protein family is composed of seven distinct members
that can form homo- and heterodimers. Dimerization leads to
their nuclear translocation and thence to modulation of the tran-
scription of target genes (O’Shea et al., 2013). Genetic deletion of
Stat3 in mice leads to early embryonic lethality (Takeda et al.,
1997).
STAT3 also has important functions outside the immune
system.Forexample,pancreas-specific (Pdx1-Cre) inactivationof
the Stat3 gene in mice causes defects in the development and
function of the pancreas, presenting mainly as a diminished
microvascular network in the islets (Kostromina et al., 2010,
2013; Lee and Hennighausen, 2005). However, beta-cell-specificell Reports 19, 281–294, April 11, 2017 ª 2017 The Author(s). 281
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Correction of STAT3K392R Mutation with CRISPR/Cas9 Rescues the Premature Differentiation Phenotype
(A) Seventeen-days differentiation protocol (see Experimental Procedures for details). Abbreviations: ACTA, activin A; B27, B-27 supplement; CHIR, CHIR-99021,
GSK-3 inhibitor; CYC, cyclopamine; F10, fibroblast growth factor 10; LDN, LDN-193189 Alk inhibitor; RA, retinoid acid; RPMI, RPMI-1640 medium. No SB was
used during stages 2 and 3 in this protocol.
(B) Schematic presentation of the targeting strategy for CRISPR/Cas9-mediated mutation correction. See also Figure S3.
(C) DNA sequences of correction template, STAT3K392R, and CORRECTED cell lines. See also Figure S6.
(D) Relative gene expression of pancreatic genes in CTRL (n = 8–15/stage independent experiments; two different cell lines), STAT3K392R (n = 7–12/stage in-
dependent experiments; three different cell lines), andCORRECTED (n = 3; three differentCORRECTED clones) cells. Data represent themean ± SEM. Statistical
analysis was performed with one-way ANOVA followed by Tukey’s test. Significant differences between STAT3K392R (STAT3) cells relative to control (CTRL) and
CORRECTED cells are shown as *p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S4.
(E) Double immunocytochemistry for NEUROG3 (NGN3) plus SOX9 and INSULIN plus CHROMOGRANIN A in CTRL, STAT3K392R, and two corrected lines after
17 days differentiation. The scale bar represents 100 mm. See also Figure S5.
(legend continued on next page)
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Stat3 mouse knockout yields more severe functional defects,
including altered secretion of insulin and improper islet organiza-
tion (Gorogawa et al., 2004). In the adult pancreas, STAT3
signaling is critical for the regeneration of beta cells (Baeyens
et al., 2014; Valdez et al., 2016).
The common polygenic forms of diabetes do not present dur-
ing the first 6 months of life, but rare cases of permanent
neonatal diabetes (PNDM) can occur during this period. These
are caused by mutations in genes important for pancreatic
beta cell development or function. Mutations in 22 distinct genes
have been associated with monogenic forms of diabetes (De
Franco and Ellard, 2015; Murphy et al., 2008), and recently, acti-
vating STAT3 mutations were identified as a cause of PNDM in
association with early onset autoimmunity. The most highly acti-
vating mutation, K392R (identified in a Finnish patient), was
found to correlate with the most severe clinical phenotype and
was localized in the DNA binding domain of STAT3 (Flanagan
et al., 2014). The patient presented with high levels of beta-cell
autoantibodies at birth (Otonkoski et al., 2000), associated with
exocrine insufficiency and pancreatic hypoplasia, along with a
general growth defect. Later, the patient developed an autoim-
mune lung disease, celiac disease-like enteropathy, and large
granular lymphocyte (LGL) leukemia (Haapaniemi et al., 2015).
Based on the strong immunological phenotype, diabetes was
presumed to be the result of an autoimmune attack on the endo-
crine pancreas. However, we hypothesized that the STAT3K392R
mutation could also directly interfere with pancreatic develop-
ment and thereby cause the pancreatic hypoplasia. In this study,
we have used patient-derived induced pluripotent stem cells
(iPSCs) to test this hypothesis. Our results show that, when
induced to differentiate into pancreatic progenitors, the
STAT3K392R cells undergo premature endocrine differentiation
due to activation of the pro-endocrine transcription factor
NEUROG3. The mechanism of this effect is based on the
increased nuclear shuttling of the mutated protein.
RESULTS
Patient-Derived iPSCs with an Activating STAT3
Mutation Differentiate Prematurely to the Pancreatic
Endocrine Lineage
We derived iPSC lines from the dermal fibroblasts of a patient
with the STAT3 K392R mutation by retroviral delivery of reprog-
ramming factors OCT4, SOX2, CMYC, and KLF4, as described
elsewhere (Toivonen et al., 2013a). Characterization of three
different iPSC lines after propagation for at least ten passages
demonstrated the expression of hallmark pluripotency markers,
the silencing of the retroviral promoters, and pluripotent differen-
tiation in vitro by embryoid body assay (Figure S1). DNA seq-
uencing of the STAT3 exon 2 verified the presence of the hetero-
zygous A to G nucleotide change causing the K392R missense
mutation in the patient-derived iPSCs (Figure 1C).(F) Quantification of NEUROG3+ cells in STAT3K392R (n = 3; three different clone
differentiation. Data represent the mean ± SEM. Statistical analysis was perform
(G) Quantification of CHGA+ and INS+ cells in STAT3K392R (n = 3; three different c
differentiation. Data represent the mean ± SEM. Statistical analysis was performThe patient-derived iPSC lines (STAT3K392R cells) were then
differentiated into pancreatic progenitors using a four-stage pro-
tocol based on previously published reports (Mfopou et al., 2010;
Nostro et al., 2011; Toivonen et al., 2013b) with minor modifica-
tions to achieve efficient differentiation from all the cell lines
(Figure S2A; Supplemental Experimental Procedures). Healthy-
donor iPSC line HEL47.2 (Trokovic et al., 2015a), HEL24.3
(Trokovic et al., 2015b), HEL46.11 (Achuta et al., 2017), and
human embryonic stem cell line H9 (Thomson et al., 1998)
were used as controls.
Both STAT3K392R and control cell lines differentiated success-
fully to definitive endoderm (DE) as shown by cell morphology
and the expression of CXCR4 (Figures S2B, S2C, and S4C),
FOXA2, and SOX17 (Figures S4A and S4B). All cell lines also pro-
gressed efficiently through primitive gut tube (day 9), posterior
foregut (day 11), and pancreatic endoderm (day 13) stages to
the final pancreatic progenitor (day 17) stage, where they ex-
pressed PDX1 homogeneously (Figure S2D). qRT-PCR analysis
across the different stages confirmed that PDX1 andNKX6.1 fol-
lowed similar expression levels and kinetics in mutant and con-
trol cells (Figure S2E). Interestingly, we found that pancreatic
endocrine cell markers NEUROG3 and insulin (INS) were signif-
icantly upregulated in the STAT3K392R cells (Figures S2F, S2J,
and S2K). Immunocytochemical quantification also revealed
increased numbers of INS+ cells (Figures S2G–S2I) at day 17.
Correction of the STAT3 Mutation Rescues the
Premature Differentiation Phenotype
The genetic background of the somatic cell donor has been
shown to affect the capability of reprogrammed iPSCs to differ-
entiate efficiently into particular cell types (Choi et al., 2015; Kyt-
ta¨la¨ et al., 2016). It is possible, therefore, that differences in the
differentiation efficiency of the iPSCs derived from the patient
versus healthy controls might disguise a mutation-specific
phenotype when using comparative differentiation protocols
in vitro. To overcome this problem and verify the premature dif-
ferentiation phenotype, we corrected the STAT3K392R mutation
in the patient iPSCs using CRISPR/Cas9 genome-editing tech-
nology. Several guide RNAs (gRNAs) were designed to target
theSTAT3 locus near themutation site and their efficiency tested
in HEK293 cells (Figure S3). After several efficiency tests (Fig-
ure S3; Supplemental Experimental Procedures), we decided
to use wild-type (WT) Cas9 (gRNA STAT3.3) combined with a
PCR-generated double-stranded DNA (dsDNA) correction tem-
plate to repair the mutation by homologous recombination. The
202-base-pair dsDNA template corrected the A to G mutant
change and introduced a silent nucleotide change, creating a
new restriction site (StyI) for screening purposes (Figures 1B
and S3B). After single-cell cloning of the electroporated patient
iPSCs by EGFP+ single-cell sorting (cloning efficiency of
45.4% ± 14.5% SD; n = 6; see Supplemental Experimental Pro-
cedures), we were able to isolate several distinct iPSC liness) and CORRECTED cells (n = 3; three different corrected clones) at day 17 of
ed with Student’s t test. *p < 0.05.
lones) and CORRECTED cells (n = 3; three different corrected clones) at D17 of
ed with Student’s t test. **p < 0.01.
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Figure 2. Extended Differentiation into Islet-like Aggregates
(A) Protocol for extended differentiation (for abbreviations, see Supplemental Experimental Procedures).
(B) Gene expression levels analyzed by qRT-PCR of pancreatic genes in CTRL (n = 4; pooled data from two healthy-donor control lines and two CORRECTED
clones) and STAT3K392R (four independent experiments) cells. Data represent the mean ± SEM. *p < 0.05; Student’s t test. Note the logarithmic scale for INS
and GCG.
(C) Immunocytochemistry analysis for PDX1, NKX6.1, SOX9, NEUROG3, CHGA, and INS after D10 differentiation in monolayer, in CTRL (healthy donor)
STAT3K392R cells. The scale bars represent 100 mm.
(legend continued on next page)
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(5.3%; 12 out 225 clones) that presented either heterozygous or
homozygous recombination with the donor template, correction
of the STAT3K392R mutation, and no Cas9-induced mutations in
the other allele (Figures 1C and S3A). The corrected cell lines A,
B, and C were karyotypically normal and did not present muta-
tions in putative off-target sites and therefore were used for sub-
sequent experiments (Figures S6A and S6B; Table S1).
The early upregulation of INS in the STAT3K392R cell lines sug-
gests that the kinetics of endocrine lineage differentiation might
be altered in these cells. Some pancreatic differentiation proto-
cols have been optimized to obtain higher numbers of INS+ cells
by inducing the expression of NEUROG3 via inhibition of trans-
forming growth factor b (TGF-b) signaling. Because this could
interfere with the effect of STAT3K392R, we omitted the TGF-b in-
hibitor SB from stages 2 and 3 of our protocol (Figure 1A) and
differentiated the STAT3-corrected iPSCs together with the
STAT3K392R and control iPSCs. The corrected cell lines also
differentiated efficiently to definitive endoderm (analyzed by cy-
tometry for CXCR4+ cells in Figure S4C), pancreatic endoderm,
and progenitors as shown by immunocytochemistry (Figures
S4D, S4E, and S5).
As expected, omission of TGF-b inhibition resulted in
decreased levels of NEUROG3, INS, and GCG at early time
points (d11 and d13) in control cells (compare Figure 1D with
S2F). Interestingly, the levels of endocrine markers NEUROG3,
NKX2.2, INS, and GCG were again distinctly higher in the
STAT3K392R cells than in the control and corrected cells (Fig-
ure 1D). Remarkably, the corrected iPSCs showed similar
expression levels to controls, indicating that correction of
the K392R mutation had rescued the premature endocrine
differentiation phenotype (Figure 1C). The results were iden-
tical with three independent corrected clones (immunocyto-
chemistry of differentiated individual clones presented in Figures
S4 and S5). These findings were further confirmed by quantifica-
tion of the cells expressing NEUROG3, CHGA, and INS (Figures
1E–1G).
We then differentiated the cells further in order to obtain more
mature beta cells, using a protocol modified from the ones
described by Pagliuca et al. (2014) and Rezania et al. (2014; Fig-
ure 2A; Supplemental Experimental Procedures). Similar to that
observed with the shorter differentiation protocols, significant
differences were observed in the expression of NEUROG3 in
the pancreatic progenitor stage (d10) in the STAT3K392R cells
compared with control and corrected cells (CTRL + CORR; Fig-
ure 2B). More abundant NEUROG3+ cells were also detected by
immunocytochemistry at d10 (Figures 2C and 2D). At the islet-
like stage (d30), the expression of GCG was significantly upre-
gulated in the STAT3K392R cells (Figure 2B), which presented
abundant endocrine cells (Figure 2E). Quantification by flow cy-
tometry at d30 revealed that there were no differences in the(D) Quantification of NEUROG3+ cells in CTRL (healthy-donor; n = 3; three differ
different corrected clones) at day 17 of differentiation. Statistical analysis was pe
between STAT3K392R (STAT3) cells and CTRL or CORRECTED cells are shown a
(E) Immunohistochemistry analysis for PDX1, NKX6.1, CHGA, INS, and GCG on
(F) Flow cytometry analysis of dissociated islet-like clusters with NKX6.1 and INS
(G) Flow cytometry analysis of dissociated islet-like clusters with GCG and INS a
positive cells. Data represent the mean ± SEM. Student’s t test; *p < 0.05.numbers of INS+ or NKX6.1+ cells (Figure 2F), whereas the
numbers of INS/GCG (glucagon) double-positive and total
GCG+ cells were significantly increased in the STAT3K392R (Fig-
ure 2G). Thus, this optimized protocol also showed that
STAT3K392R cells upregulated NEUROG3 prematurely, resulting
in increased endocrine differentiation, which was biased toward
the GCG+ alpha cell lineage.
To examine the possible genes and pathways causing the
premature endocrine differentiation in STAT3K392R iPSCs, we
performed RNA-seq at day 11 of differentiation with the modi-
fied protocol. In mutant versus corrected cells, 777 genes
were upregulated and 206 downregulated (fold change R
1.5; Table S2). Ingenuity pathway analysis showed that among
the most significantly upregulated genes in the mutant versus
corrected cells were NEUROG3 and its downstream targets
(Figure 3A). It also suggested that NEUROG3 is the main puta-
tive upstream regulator of the detected overexpressed genes
(Figure 3B). No significant changes were detected in genes
or pathways known to regulate NEUROG3 (e.g., Notch or
TGF-b signaling pathways) or other endocrine markers (Table
S2). We performed gene ontology (GO) analysis on the
differentially expressed genes to identify biological processes
associated with STAT3K392R. Consistent with the increased
endocrine cell differentiation, genes differentially expressed
in STAT3K392R were associated with ion transport, transmem-
brane transport, synaptic signaling, and RNA biosynthesis
(Figure S6C). These results demonstrate that the activating
STAT3K392R mutation drives pancreatic progenitors to differ-
entiate into endocrine cells by inducing the premature expres-
sion of NEUROG3.
The Mutant Phenotype Is Not Explained by Differential
Phosphorylation of STAT3
Activation of STAT3-mediated signaling pathways with IL-6 has
previously been shown to increase NEUROG3 expression and
differentiation toward endocrine lineage (Gutteridge et al.,
2013). To determine whether ligands for STAT3 signaling would
induce NEUROG3 expression, we studied the phosphorylation
status of ectopically expressed WT and mutant STAT3 in
HEK293 cells. Cells were either left untreated or stimulated
with IL-6 or LIF, known inducers of the STAT3 signaling pathway
(Baeyens et al., 2006, 2014). Under non-stimulating condi-
tions, the phosphorylation of residue Y705 was increased in
STAT3K392R-transfected cells (Figure S7A). As shown previously,
the STAT3K392R was more transcriptionally active than STAT3
WT in HEK293 under both basal and IL-6-stimulated conditions
using a STAT3-luciferase reporter assay (Figure S7B; Flanagan
et al., 2014). Interestingly, mutagenesis of the Y705 phosphory-
lation site revealed that the increased transcriptional activity of
STAT3K392R depends only partially on Y705 phosphorylation. Aent cell lines), STAT3K392R (n = 4; HEL72D), and CORRECTED cells (n = 4; two
rformed with one-way ANOVA followed by Tukey’s test. Significant differences
s *p < 0.05 and **p < 0.01.
sections of islet-like clusters at day 30. The scale bars represent 100 mm.
antibodies. Data represent the mean ± SEM.
ntibodies. Results are presented separately for single- and double-hormone-
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Figure 3. Differentially Expressed Genes between STAT3K392R and Mutation-Corrected Clones Reveal a NEUROG3-Regulated Network
(A) The most up- and downregulated genes related with endocrine differentiation in STAT3K392R cells. NEUROG3 levels are marked in red. See also Figure S6.
(B) Interaction network of genes regulated by NEUROG3 differentially expressed in STAT3K392R cells.Y705-independent activity component was retained in both
basal and cytokine-stimulated conditions (Figure S7B).
In order to discover whether activation of STAT3 signaling
pathways could mimic the mutation-associated phenotype, we
stimulated the differentiating cells with IL-6 or LIF (Baeyens
et al., 2014) during stages 2 and 3 (days 5–13; Figure 4A), after
confirming that interleukin-6 receptor (IL-6R) was expressed in
the cells (Figure S7D). We found that there was no increase of
NEUROG3 expression levels or other endocrine markers upon
stimulation (Figure 4A). Because STAT3 signaling status might
be cell type and context specific, we also analyzed the phos-
phorylation of STAT3 at day 11 of differentiation. Although
STAT3 Y705 was strongly phosphorylated after IL-6 stimulation
(Figures 4B and 4C), in all cell lines, we did not detect significant
differences in STAT3 phosphorylation levels between cell lines,
with or without IL-6 stimulation. Similar results were observed
at the pluripotent stage (Figure S7C).
These results suggest that STAT3 protein phosphorylation is
not the main mechanism responsible for the STAT3K392R muta-
tion-induced premature endocrine differentiation.286 Cell Reports 19, 281–294, April 11, 2017K392R Mutation Does Not Alter the Intrinsic DNA-
Binding Ability of STAT3 to NEUROG3 Promoter
Electrophoretic mobility shift assay and oligonucleotide pull-
down assay were used to analyze the effect of K392R mutation
on STAT3DNA-binding ability. As expected, STAT3DNA binding
was highly dependent on induction of STAT3 phosphorylation
by pervanadate stimulation of COS-7 cells as assayed by elec-
trophoretic mobility shift assay (EMSA), where overexpression
of STAT3 resulted in an increase in the STAT3 protein-DNA com-
plex (Figure 5A). We did not, however, observe any difference
between the DNA-binding efficiency of overexpressed WT and
STAT3K392R. Similar results were obtained with oligonucleotide
pull-downs, where pervanadate treatment caused increased
STAT3 DNA binding to the IRF-1 oligo (containing a canonical
STAT3-binding motif) to the same degree with WT and
STAT3K392R protein (Figure 5B). In HEK293T cells, overexpres-
sion of STAT3 was sufficient to induce DNA binding without per-
vanadate induction (Figure 5C). Importantly, binding to the previ-
ously reported STAT3 binding site in the NEUROG3 promoter
sequence (Kaucher et al., 2012) was similar to that at the IRF-1
Figure 4. Premature Differentiation Is Not Caused by Increased STAT3-Y705 Phosphorylation
(A) Relative gene expression analyzed by qRT-PCR of pancreatic progenitor genes (PDX1 and NKX6.1) and differentiation markers NEUROG3 (NGN3), INS, and
GCG in CTRL and STAT3K392R cells with and without IL-6 or LIF stimulation during stages 2 and 3 of differentiation to test whether activation of STAT3 signaling
pathway is enough to mimic effect of STAT3 mutation. Data represent the mean ± SEM of two to five independent experiments. Statistical analysis with one-way
ANOVA did not reveal significant differences between treatment groups.
(B) Western blot analysis of total STAT3 and pSTAT3-Y705 in pancreatic progenitors representing either STAT3K392R (two different clones; HEL72.1 and HEL72D)
or controls (two corrected lines and one control line) at 11 days of differentiation. Exposure time for STAT3 blots was for 1 s and for pSTAT3 blots 10 min.
Quantitative analysis was performed by normalizing values against ACTIN expression, and the data are expressed relative to CTRL. Data represent the
mean ± SEM. See also Figure S7.
(C) The same cells as in (B) after IL-6 stimulation for 30 min. Exposure time for STAT3 was 1 s and 22 s for pSTAT3. Quantitative analysis was performed by
normalizing values against ACTIN expression, and the data are expressed relative to CTRL. Data represent the mean ± SEM.sequence, and no difference was observed in the DNA-binding
properties of the WT and STAT3K392R proteins (Figures 5B
and 5C).
To study further the interaction of STAT3 with the human
NEUROG3 promoter in pancreatic cells, we generated a lucif-
erase reporter construct, which was expressed together with
different STAT3 mutants in the PANC1 pancreatic ductal cell
line. All three tested STAT3 variants, WT, STAT3K392R, andSTAT3Y640F, a cancer-associated powerfully activating mutant
with increased nuclear translocation (Pilati et al., 2011), pre-
sented increased NEUROG3-luciferase activity without IL-6
stimulation (Figure 5D). STAT3 activity luciferase reporter assay
was performed in parallel for comparison (Figure 5E). Activation
of the NEUROG3 promoter was only detectable in PANC1 cells,
but not in HEK293 (data not shown). These results show
that both WT and mutant STAT3K392R bind to the NEUROG3Cell Reports 19, 281–294, April 11, 2017 287
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Figure 5. K392R Mutation Does Not Alter the Intrinsic DNA-Binding Ability of STAT3
(A) COS7 cells were transfected with an empty vector or expression vector for STAT3 (S3 WT) or STAT3K392R mutant (S3 KR). Cells were stimulated, where
indicated, with pervanadate for 20 min to induce STAT3 phosphorylation and nuclear extract used in the binding reaction with an infrared-dye-labeled STAT3
consensus sequence. The complexes were resolved on a native polyacrylamide gel and visualized with LI-COR Odyssey instrument.
(B) Oligonucleotide pull-down with the indicated oligonucleotides using whole-cell extracts of COS-7 cells transfected as in (A). Oligonucleotide-bound proteins
were resolved by SDS-PAGE, blotted and detected with a STAT3 antibody.
(C) Oligonucleotide pull-down using whole-cell extracts of HEK293T cells transfected as in (A) and detected by STAT3 immunoblotting.
(D) NEUROG3 promoter activity in PANC1 cells after transfection of cells with empty vector (E/V), normal STAT3 (STAT3 WT), STATK392R, or STAT3Y640F (highly
activatingSTAT3mutation) in unstimulated (IL-6) and stimulated (+IL-6) conditions.Data represent themean±SEMof three independent experiments. Statistical
significance against empty vector *p < 0.05; ***p < 0.001; statistical significance against K392R a = p < 0.05; one-way ANOVA followed by Tukey’s test.
(E) STAT3-regulated SIE (sis-inducible element) promoter activity in PANC1 cells in unstimulated (IL-6) and stimulated (+IL-6) conditions. Statistics as in (D).promoter in pancreatic cells and that the STAT3K392R-associ-
ated increase in NEUROG3 transcription is not due to an
increased DNA-binding affinity.
K392R Mutation Increases STAT3 Nuclear Localization
Because the disease phenotype could not be fully explained by
altered phosphorylation or DNA binding of STAT3K392R, we
reasoned that the mutation might change the interactions of
STAT3 with other proteins. Stable, inducible HEK293 cell lines
of WT and STAT3K392R were generated to identify differences
in interaction partners by biotin proximity assay (Roux et al.,
2012; Figure 6A). Mass spectrometric quantification of the288 Cell Reports 19, 281–294, April 11, 2017STAT3 interacting partners showed significantly increased inter-
actions with proteins involved in transcriptional regulation
(STAT1 [known STAT3 partner], GSE1, TLE3, MTA1, BCOR,
and DIDO1) and chromatin remodeling (SMARCC2, YEATS2,
SMARCA4,WDR5, andMYSM1) for STAT3K392R. Similarly, inter-
action of STAT3K392R with nuclear pore proteins was elevated
(NUP50, NUP62, and NUP153). Additionally, the mutant inter-
acted more effectively with importin subunit alpha-1 (IMA1),
whereas its interaction with the export protein RANBP3 was
decreased (Figure 6A). Analysis of the phospho-modified pep-
tides showed similar degree of phosphorylation on S727
(15.6% for STAT3K392R versus 10.7% for WT).
AB C D
Figure 6. K392R Mutation Increases STAT3
Nuclear Localization
(A) Biotin proximity assay identifies interactions
between STAT3 and proteins involved in tran-
scriptional regulation (STAT1 [known STAT3 part-
ner], GSE1, TLE3, MTA1, BCOR, and DIDO1),
chromatin remodeling (SMARCC2, YEATS2,
SMARCA4, WDR5, and MYSM1), and nuclear
transport (NUP50, RANBP3, NUP62, IMA1,
NU153, and NXF1). Compared to the STAT3 WT,
STATK392R in general shows significantly increased
interactions with nuclear proteins and notably
transport proteins involved in nuclear import,
suggesting an increased nuclear translocation.
*, significantly different interacting proteins; p <
0.05; Student’s t test; n = 3. **, detected proteins
interacting only with STAT3 K392R or WT.
(B) Nuclear localization of STAT3 determined by
manual blinded scoring of HEK293 overexpressing
STAT3 WT, STAT3 K392R, or STAT3 Y640F,
a mutant with increased nuclear localization.
n = 16–30 individually scored cells. Statistical
analysis was performed with one-way ANOVA
with Tukey’s multiple comparison test. Differences
between the conditions are marked in the figure.
**p < 0.01; ***p < 0.001.
(C) Nuclear localization of STAT3 determined by
measuring nuclear to cytoplasmic ratio of STAT3
versions overexpressed in HEK293 cells as in (B).
n = 26–30 individually measured cells. Statistical
analysis was performed with one-way ANOVA with
Tukey’s multiple comparison test. Differences
between the conditions are marked in the figure.
*p < 0.05; ***p < 0.001.
(D) Nuclear localization of STAT3 determined by
quantification of nuclear intensity of stained STAT3 WT and STAT3 K392R-overexpressing HEK293 cells, treated or not with IL-6. Data represent mean ± SEM;
n = 3 biological replicates. Analysis was performed on five random fields imaged per well, with an average of 63 nuclei/image, 315 nuclei/well, and 945 nuclei/
condition. Statistical analysis was performed with one-way ANOVA with Tukey’s multiple comparison test. Stars mark the differences between measured
condition and WT STAT3. *p < 0.05.Thus, we hypothesize that STAT3K392R is shuttled more effec-
tively into the nuclear compartment, and this was confirmed by
immunocytochemical analysis of STAT3 localization (Figures
6B–6D).
Transplanted STAT3K392R Cells Differentiate
Preferentially into Alpha Cells
To study the functional outcome of the STAT3K392R mutation
in mature endocrine cells, we transplanted control and
STAT3K392R-differentiated cells under the kidney capsule of
immunodeficient non-obese diabetic (NOD)-severe combined
immunodeficiency (SCID)-gamma (NSG) mice. Three months
after transplantation, grafts presented organized cytoarchitec-
ture (Figures 7A and 7B) with abundant endocrine cells. Closer
examination of the endocrine cell numbers showed predomi-
nantly GCG+ cells at the expense of INS+ cells in theSTAT3K392R
grafts (Figure 7C). The percentage of double-positive GCG+/
INS+ polyhormonal cells was overall low, 2.27% and 1.16% of
total for CTRL and STAT3K392R grafts, respectively, and not
significantly different. Interestingly, these results are concordant
with the clinical features in the patient at birth, demonstrating
normal levels of circulating glucagon but only traces of C-pep-
tide (Otonkoski et al., 2000; unpublished data).DISCUSSION
This experimental project was stimulated by a unique experi-
ment of nature: the identification of an activating STAT3mutation
in a patient with permanent neonatal diabetes, pancreatic hypo-
plasia, growth failure, and several organ-specific autoimmune
features (Otonkoski et al., 2000; Flanagan et al., 2014; Haapa-
niemi et al., 2015). Previous reports have focused mainly on
the immune system as the target of the pathology associated
with activating STAT3 mutations. However, several clinical
features, such as the pancreatic hypoplasia and primary growth
failure, could also be due to organ-specific effects of the muta-
tion outside the immune system. Using pancreatic differentiation
of patient-derived iPSCs, we demonstrate that the K392R
mutation in STAT3 leads to premature differentiation of pancre-
atic progenitors. This effect is mediated through activation of
NEUROG3, a master regulator of endocrine pancreatic develop-
ment. The mechanism does not involve activation of classical
STAT3 signaling pathways but appears to be due to increased
shuttling of the mutant STAT3 protein into the nucleus, where it
can bind and induce the NEUROG3 promoter.
NEUROG3 is a basic helix-loop-helix transcription factor
acting as the master regulator of pancreatic endocrine cellCell Reports 19, 281–294, April 11, 2017 289
Figure 7. Prematurely Differentiated STATK392R Cells Form GCG-Positive Cells after Transplantation
(A) Hematoxylene-Eosin (HE) staining of pancreatic grafts derived from CTRL (healthy donor) and STAT3K392R iPSCs grafts removed at 3 months after trans-
plantation under the kidney capsule of NSG mice (borderline between kidney and graft tissue marked by a dashed line). Four grafts were produced using the
30-day, seven-stage protocol for islet-like aggregates (Figure 2; two derived from healthy-control iPSCs and two from mutant iPSCs) and four grafts using the
17-day, four-stage pancreatic progenitor protocol (Figure 1; two derived from healthy-control iPSCs and two frommutant iPSCs), totally eight different grafts, four
per genotype. The scale bars represent 200 mm.
(B) Double immunohistochemistry of graft sections for INS + CHGA (top), INS+ GCG (middle), and PDX1 + C-PEPTIDE (CPEP) (bottom). The scale bars represent
100 mm.
(C) Quantification of relative proportion of INS+, GCG+, and double-positive cells in CTRL and STAT3K392R grafts (n = 4 individual grafts per genotype, totaling
eight different grafts). Statistical analysis was performed with Student’s t test; **p < 0.01.differentiation. Lack of NEUROG3 leads to developmental failure
of endocrine cells in mouse (Gradwohl et al., 2000; Schwitzgebel
et al., 2000) and human (McGrath et al., 2015; Pinney et al., 2011;
Rubio-Cabezas et al., 2011). The expression level of NEUROG3
is crucial for the endocrine commitment of the pancreatic pro-
genitors (Wang et al., 2010), whereas its timing determines the
allocation of the different endocrine cell types (Johansson
et al., 2007). In support of this, forced overexpression of Neurog3
during early development results in pancreatic hypoplasia in
transgenic mouse models (Apelqvist et al., 1999; Schwitzgebel
et al., 2000) and biased differentiation of endocrine progenitors
toward alpha cells (Johansson et al., 2007). Therefore, the
abnormal NEUROG3 upregulation observed in patient-derived
iPSCs would be expected to lead to pancreatic progenitor pool
depletion, thereby explaining the pancreatic hypoplasia in the290 Cell Reports 19, 281–294, April 11, 2017patient. More advanced differentiation of the patient cells
in vitro and after transplantation revealed strongly biased differ-
entiation toward alpha cells at the expense of beta cells (Figures
2 and 7). Similar biased differentiation has been previously re-
ported in PSC-derived pancreatic progenitor grafts (Rezania
et al., 2011, 2013). The expression of NEUROG3 before the onset
of NKX6.1 in the pancreatic progenitors results in polyhormonal
cells in vitro that differentiate into alpha cells after transplanta-
tion. This can be controlled if NEUROG3 is induced in progeni-
tors expressing NKX6.1 (Nostro et al., 2015; Rezania et al.,
2013; Russ et al., 2015). These observations on the premature
induction of NEUROG3 are consistent with our findings on the
effect of STAT3K392R mutation.
Furthermore, these experimental results go well together with
the clinical data, showing only traces of circulating C-peptide
(less than 0.05 nmol/L throughout life) but a normal level of
plasma glucagon (77 ng/L at the age of 2 months and 124 ng/L
at the age of 18 years), together with a rudimentary pancreas
in MRI (Otonkoski et al., 2000). These findings are also entirely
consistent with the transgenic mouse models of NEUROG3
overexpression in pancreatic progenitors (Apelqvist et al.,
1999; Johansson et al., 2007).
NEUROG3 expression is activated by upstream transcription
factors, such as PDX1, FOXA2, SOX9, HNF6, GLIS3, and
HNF1B (Jacquemin et al., 2000; Kim et al., 2012; Lee et al.,
2001; Oliver-Krasinski et al., 2009; Pan and Wright, 2011; Sey-
mour et al., 2008; DeVas et al., 2015). In addition, Notch signaling
regulates the levels ofNEUROG3post-transcriptionally througha
lateral inhibitionmechanism (Afelik and Jensen, 2013). TheNotch
downstream effector Hes1 regulates proliferation of pancreatic
progenitors and endocrine differentiation (Pan and Wright,
2011), whereas inhibition of Notch results in premature differenti-
ation of islet cells (Jensen et al., 2000). However, we did not
detect any significant changes in the expression of NEUROG3
upstream regulators or in the genes associated with Notch
signaling. A non-canonical Notch signaling axis involving phos-
phatidylinositol 3-kinase (PI3K)-Akt-mTOR, STAT3-Ser phos-
phorylation, and HES3 has also been suggested to control
NEUROG3 activation (Masjkur et al., 2016), but we could not
detect any changes in HES3 transcriptional levels in our experi-
ments (data not shown). Thus, the premature upregulation of
NEUROG3 caused by the STAT3 mutation does not seem to be
mediated by perturbations in the known developmental mecha-
nisms controlling NEUROG3.
STAT3 signaling has been studied in the context of pancre-
atic plasticity in diabetic mouse models, where it mediates
the activation of Neurog3 in acinar cells that reprogram to
beta cells (Baeyens et al., 2006, 2014). In mice rendered dia-
betic by selective beta cell destruction with alloxan, treatment
with epidermal growth factor (EGF) and ciliary neurotrophic fac-
tor (CNTF) (a STAT3 signaling pathway ligand) resulted in
increased phosphorylation of STAT3, leading to the upregula-
tion of Neurog3 (Baeyens et al., 2014). Similar results have
been shown in human exocrine pancreatic cells transduced
with constitutively active forms of STAT3 and MAPK (Lemper
et al., 2015) and in the human ductal cell line PANC1 treated
with proinflammatory cytokines (Valdez et al., 2016). Using a
global bioinformatic approach and a causal reasoning algo-
rithm, Gutteridge and colleagues suggested that STAT3
signaling pathway is involved in the activation of NEUROG3
in differentiating human embryonic stem cells (Gutteridge
et al., 2013). The studies described above show that JAK-medi-
ated phosphorylation of STAT3 results in NEUROG3 transcrip-
tional activation. However, several lines of evidence suggest
that mutant STAT3K392R exerts its effects independently of
phosphorylation status. Thus, stimulation of the pancreatic
endoderm cells with IL-6 or LIF resulted in Y705 STAT3 phos-
phorylation but did not increase NEUROG3 activation in our
experiments (Figures 4C, 4D, and S7). This is consistent with
the retention of increased transcriptional activity in the Y705F
mutant STAT3K392R (Figure S7B). Interestingly, the nuclear
import of STAT3 is independent of tyrosine phosphorylation
(Liu et al., 2005), and STAT3 has been suggested to functionas a transcriptional activator and a chromatin organizer in its
unphosphorylated form (Sehgal, 2008; Timofeeva et al., 2012).
STAT3 has been reported to bind to the Neurog3 promoter in
differentiating mouse spermatogonial cells (Kaucher et al.,
2012). We demonstrate by oligonucleotide pull-down and lucif-
erase reporter assay that both WT and STAT3K392R bind to the
NEUROG3 promoter independently of STAT3 phosphorylation
status, further suggesting the role of unphosphorylated STAT3
in regulating NEUROG3 (Timofeeva et al., 2012).
Biotin proximity assay showed increased interaction of mutant
STAT3 with several nuclear pore complex proteins, transcrip-
tional regulators, and chromatin remodelers. These differential
interactions suggest an increased nuclear translocation of the
mutant protein, which was further confirmed by quantitative
immunofluorescencemicroscopy (Figure 6B). Although the loca-
tion of the mutation within the DNA-binding domain (DBD) of
STAT3 would suggest an effect on STAT3 DNA-binding proper-
ties, our data show that both WT and STAT3K392R bind to DNA
with similar affinities. Collectively, our results suggest strongly
that increased nuclear localization of STAT3K392R is the main
mechanism for increased activation of NEUROG3.
In summary, our study highlights a pathogenetic mechanism
associated with organ-specific dysregulation of a centrally
important signal transducer, STAT3. The pathogenetic mecha-
nisms of activating STAT3 mutations have previously been stud-
ied in the context of the immune and hematopoietic systems
(Koskela et al., 2012). However, our results demonstrate that,
in addition to the early onset autoimmunity, the same mutation
leads to a primary developmental defect in pancreatic organo-
genesis. Further studies will be needed to establish whether a
similar developmental mechanism in the bone growth plates
may underline the severe primary overall growth defect of the pa-
tient. Finally, our experimental approach demonstrates the
versatility of iPSCs combined with genome editing as powerful
tools that can be applied to elucidate organ-specific pathoge-
netic mechanisms. Whereas this study relies on the derivation
of iPSCs from a single patient carrying the STAT3K392R mutation,
follow-up studies are needed with other activating STAT3 muta-
tions, using both patient-derived iPSCs and engineering of the
mutations in standard human pluripotent stem cell (hPSC) lines.
EXPERIMENTAL PROCEDURES
Additional details are provided in Supplemental Experimental Procedures.
Patient Samples and the Use of Animals
Human induced pluripotent stem cell (hiPSC) lines used in this study were
generated after informed consent approved by the Coordinating Ethics Com-
mittee of the Helsinki and Uusimaa Hospital District (no. 423/13/03/00/08). An-
imal care and experiments were approved by the National Animal Experiment
Board in Finland (ESAVI/9978/04.10.07/2014). NSG (Jackson Laboratories;
005557) male mice, aged 3–12 months, were used for this study.
Cell Culture
iPSC lines HEL72.1, HEL72A, and HEL72D were derived from STAT3K392R
patient skin fibroblasts using retroviral-based reprogramming as described
elsewhere (Toivonen et al., 2013a). Human iPSC line HEL47.2 (derived from
83-year-old male skin fibroblast), HEL24.3, and HEL46.11 (derived from
human neonatal foreskin fibroblast) were reprogrammed using Sendai
virus technology as described elsewhere (Trokovic et al., 2015a, 2015b).Cell Reports 19, 281–294, April 11, 2017 291
HEL47.2, HEL24.3, and HEL46.11, together with human embryonic stem cell
(ESC) line H9 (Thomson et al., 1998), were used as healthy-donor controls.
Undifferentiated cells were cultured on Matrigel (BD Biosciences)-coated
plates in E8 medium (Life Technologies; A1517001) and passaged with
5 mM EDTA (Life Technologies; 15575-038).
Differentiation
The cells were differentiated using a 17-day protocol (see Figure 1A) described
earlier (Toivonen et al., 2013b) or 30-day protocol (see Figure 2A). Additional
details are provided in Supplemental Experimental Procedures.
Genome Editing
Two million patient-derived iPSCs were electroporated with 6 mg of CAG-
Cas9-T2A-EGFP-ires-Puro (deposited in Addgene, plasmid no. 78311,
together with detailed protocols for its use), 500 ng of gRNA-PCR STAT3.3
product, and 6 mg of dsDNA correction template PCR product using Neon
Transfection system (Thermo Fisher; 1,100 V; 20 ms; two pulses). Cells were
single-cell sorted, expanded, and screened for recombination with the donor
template. Positive clones were validated by Sanger sequencing. See also Sup-
plemental Experimental Procedures.
Biotin Proximity Assay, Mass Spectrometry, Protein Identification,
and Quantification
For each BioID analysis, approximately 5 3 10E7 HEK293 cells were induced
with 2 mg/mL tetracycline (for STAT3 WT and STAT3K392R expression induc-
tion) and 50 mM biotin (for activation of the BirA -biotin ligase) for 24 hr. Cells
were harvested and lysates prepared and loaded to Strep-Tactin Sepharose
beads (400 mL 50% Slurry; IBA). Bound proteins were eluted with 2 3
300 mL freshly prepared 0.5 mM D-biotin (Thermo Fisher Scientific).
Liquid chromatography-mass spectrometry (LC-MS/MS) and data analysis
was performed as described earlier (Ka¨mpja¨rvi et al., 2016). SEQUEST search
algorithm in Proteome Discoverer software (Thermo Fisher Scientific) was
used for peak extraction and protein identification. Proteins detected with
<20% frequency or 3-fold higher abundance (spectral counts) compared to
the controls were classified as high-confidence interacting proteins. Proteins
were identified and quantified using Andromeda search engine combined
with MaxQuant proteomics software (Cox et al., 2011; Cox and Mann,
2008). Raw data were searched against the human component of the Uni-
ProtKB database (release 2014_11) complemented with trypsin and tag
sequences.
Statistical Analysis
Statistical analysis was performed with Student’s unpaired t test or one-way
ANOVA followed by Tukey’s multiple comparison post hoc test using Graph-
Pad Prism software (GraphPad Software). Separation between homoscedas-
tic (equal variance) and heteroscedastic (unequal variance) type of t test was
analyzed with F test. p values under 0.05 were considered statistically signif-
icant (*p < 0.05; **p < 0.01; ***p < 0.001).
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